Six U.S. scientists have been awarded $1.25 million each over 5 years to conduct high-risk, high-reward cancer immunology research with potential to transform cancer treatment
Latest analysis from the Cancer Research Institute of the global landscape of cellular immunotherapies, including R&D trends and real-world usage, highlights key challenges including effective solid tumor targeting, manufacturing complexities, and commercial access to approved therapies
Awareness and educational program offerings for cancer patients and caregivers about the latest advances in cancer immunotherapy shared over 30 days in June
First patients dosed in phase 2 platform clinical trial testing novel immunotherapy combinations in highly malignant ovarian cancer.
CRI’s latest analysis of the PD1/PDL1 immuno-oncology landscape confirms trends in trial design and patient enrollment, points to robust pipeline of new agents in clinical development
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.